Clinical Trial Update: Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating intravitreal ranibizumab to prevent radiation maculopathy after plaque radiotherapy in uveal melanoma, with current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiation Maculopathy
• Radiation Retinopathy
• Uveal Melanoma

Drugs mentioned

• Ranibizumab (Lucentis) (ranibizumab)

Snippet

Sponsor: Shields, Shields and Associates | Conditions: Uveal Melanoma, Radiation Retinopathy | Phase 4 | Status: UNKNOWN